LabCorpTo Follow Pivotal Role In Clinical Trial Of Merck & Co.’s Keytruda By Offering PD-L1 Companion Diagnostic

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the nationwide availability of a new FDA-approved companion diagnostic, the PD-L1 IHC 22C3 pharmDx assay by Dako, an Agilent Technologies company, to assess the eligibility of non-small cell lung cancer (NSCLC) patients for treatment with pembrolizumab (Keytruda).

Help employers find you! Check out all the jobs and post your resume.

Back to news